In 2026, radiopharmaceuticals can be described as having moved from niche palliative care toward becoming a more central pillar of precision oncology, a maturation attributed in part to the commercial success of Novartis’s Pluvicto. For 2026, the investment thesis is framed as shifting away from conceptual validation and toward execution, with two trends emphasized: diversification … [Illustrations] Radiopharmaceuticals in 2026: Alpha Emitters, Industrial Scale, and the Supply Chain as Strategy Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.